NFKB1 and colorectal carcinoma: In-vivo studies confirmed that ORI first inhibited the expression of AP-1 and then downregulated the expression of p38 and NF-κB, suggesting that ORI may exert anti-CRC effects through the NF-κB signaling pathway and P38-dependent MAPK signaling pathway.